These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 19197453

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jiménez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM.
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [Abstract] [Full Text] [Related]

  • 6. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA.
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [Abstract] [Full Text] [Related]

  • 7. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
    Murray RD, Melmed S.
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
    [Abstract] [Full Text] [Related]

  • 8. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.
    Kendall-Taylor P, Miller M, Gebbie J, Turner S, al-Maskari M.
    Pituitary; 2000 Oct; 3(2):61-5. PubMed ID: 11141697
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological Acromegaly Treatment: Cost-Utility and Value of Information Analysis.
    Leonart LP, Riveros BS, Krahn MD, Pontarolo R.
    Neuroendocrinology; 2021 Oct; 111(4):388-402. PubMed ID: 32299084
    [Abstract] [Full Text] [Related]

  • 10. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
    Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Grossman AB.
    Clin Endocrinol (Oxf); 2000 Dec; 53(6):719-24. PubMed ID: 11155094
    [Abstract] [Full Text] [Related]

  • 11. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
    Bonert V, Mirocha J, Carmichael J, Yuen KCJ, Araki T, Melmed S.
    J Clin Endocrinol Metab; 2020 Sep 01; 105(9):. PubMed ID: 32754748
    [Abstract] [Full Text] [Related]

  • 12. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K, Cheer S, Wagstaff AJ.
    Drugs; 2003 Sep 01; 63(22):2473-99. PubMed ID: 14609359
    [Abstract] [Full Text] [Related]

  • 13. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.
    Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D.
    J Clin Endocrinol Metab; 2005 Aug 01; 90(8):4465-73. PubMed ID: 15886238
    [Abstract] [Full Text] [Related]

  • 14. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
    Colao A, Auriemma RS, Pivonello R.
    Pituitary; 2016 Apr 01; 19(2):210-21. PubMed ID: 26290466
    [Abstract] [Full Text] [Related]

  • 15. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly.
    Turner HE, Lindsell DR, Vadivale A, Thillainayagam AV, Wass JA.
    Eur J Endocrinol; 1999 Dec 01; 141(6):590-4. PubMed ID: 10601961
    [Abstract] [Full Text] [Related]

  • 16. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G.
    Clin Endocrinol (Oxf); 2005 Sep 01; 63(3):342-9. PubMed ID: 16117824
    [Abstract] [Full Text] [Related]

  • 17. Somatostatin agonists for treatment of acromegaly.
    Ben-Shlomo A, Melmed S.
    Mol Cell Endocrinol; 2008 May 14; 286(1-2):192-8. PubMed ID: 18191325
    [Abstract] [Full Text] [Related]

  • 18. Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study.
    Razzore P, Colao A, Baldelli R, Gaia D, Marzullo P, Ferretti E, Ferone D, Jaffrain-Rea ML, Tamburrano G, Lombardi G, Camanni F, Ciccarelli E.
    Clin Endocrinol (Oxf); 1999 Aug 14; 51(2):159-64. PubMed ID: 10468985
    [Abstract] [Full Text] [Related]

  • 19. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K, Lamberts SW.
    Endocr Relat Cancer; 2016 Dec 14; 23(12):R551-R566. PubMed ID: 27697899
    [Abstract] [Full Text] [Related]

  • 20. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
    Waśko R, Bolko P, Kostrzewski J, Horst-Sikorska W, Liebert W, Sowiński J.
    Pol Arch Med Wewn; 2001 Aug 14; 106(2):693-8. PubMed ID: 11926144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.